1.Medication Regularity Study on Prescriptions Containing Asini Corii Colla Based on Literature
Yongshui HU ; Chuanliang JI ; Yan ZHANG ; Lu ZHANG ; Zhaoqi PENG ; Shihuan TANG
Chinese Journal of Information on Traditional Chinese Medicine 2015;(9):41-43,44
Objective To discuss the medication regularity of prescriptions containing Asini Corii Colla;To provide data support for clinical compatibility application of Asini Corii Colla.Methods Totally 2635 articles about prescriptions containing Asini Corii Colla were retrieved from CNKI from Jan. 1995 to Dec. 2012. TCM Inheritance Support System V2.0 was employed to conduct frequency analysis and association rules analysis, with a purpose to determine the frequency, indications of disease, indications of syndrome and medicine core combination of common prescriptions containing Asini Corii Colla.Results The 2635 prescriptions containing Asini Corii Colla involved 1197 Chinese herbal medicines, 34 kinds of which were used in extremely high frequency (frequency>200). 30 kinds of indications of disease were treated in the high frequency (frequency>20). 32 kinds of indications of syndrome were treated in the high frequency (frequency>20). The combination of Glycyrrhizae Radix et Rhizoma, Angelicae Sinensis Radix and Asini Corii Colla showed the highest frequency in all three herbal combinations (486 times), and Atractylodix Macrocephalae Rhizoma, Asini Corii Colla, Codonopsis Radix and Astragali Radix showed the highest frequency in all four herbal combinations (272 times).Conclusion Most of compatibility them can enrich blood and tonify qi, and have major functions for gynecological diseases and major syndromes of qi-blood deficiency.
2.Open radical prostatectomy for locally advanced prostate cancer: report of 132 cases
Fei LIU ; Yue YANG ; Rui CHEN ; Xinwen NIAN ; Ji LYU ; Bo YANG ; Xu GAO ; Jianguo HOU ; Chuanliang XU ; Shancheng REN ; Yinghao SUN
Chinese Journal of Urology 2017;38(6):438-441
Objective To investigate the safety and effectiveness of open radical prostatectomy (ORP) for locally advanced prostate cancer (LAPC).Methods From January 2012 to April 2017,132 cases underwent ORP were included.The mean age was 65.1 years old (ranged 41 to 83 years old),median PSA was 28.9 ng/ml (ranged 1.2 to 319.7 ng/ml) and mean Glcason score was 8.0(ranged 6.0 to 10.0).The number of clinical stage T3aN0,T3bN0,T4N0 and T1 ~4N1 were 92 cases(69.7%),20 cases (15.2%),8 cases (6.1%) and 12 cases (9.0%),respectively.Results The median length of hospital day,mean operative time and median blood loss were 9 d,180 min and 350 ml respectively.The intraoperative complication rate was 3.0% (4/132),including 2 rectum injury and 2 iliac vessel injury.Pathological tumor stage revealed that ≤ pT2 N0 7 cases (5.3%),pT3a N0 61 cases (46.2%),pT3b N0 38 cases (28.8%),pT4N0 12 cases (9.1%) and pT1~4N1 14 cases (10.6%).The mean Gleason score was 8.0 (ranged 6 tol0).The numbers of patients with perineural invasion,seminal vesicle invasion and positive surgical margin were 81 cases (61.4%),49 cases (37.1%) and 41 cases (31.1%) respectively.The median follow-up duration was 24.1 (ranged 1.8 to 62.2) months.The rate of postoperative complications was 3.0% (4/132) including 1 urethral stricture,1 wound infection,1 intestinal fistula and 1 lymphatic fistula.The rates of patients with urinary continence 1,3,6 and 12 months after surgery were 30.4% (38/125)、63.9% (76/119)、72.6% (82/112)、89.1% (90/101).The rates of adjuvant hormonal therapy and radiotherapy were 34.1% (45/132) and 38.6% (51/132).One patient (0.8%) died of lung cancer.The rate of biochemical recurrence(BCR) was 25.8% (34/132).The 5-year BCRfree survival rate was 57.2% (95% CI 41.9% ~ 70.6%).Conclusion The oncological control and functional recovery outcomes of ORP for locally advanced prostate cancer were reliable.
3.Soluble PD-L1 as a prognostic factor for advanced acral and mucosal melanoma
WANG Xuan ; KONG Yan ; CUI Chuanliang ; CHI Zhihong ; SHENG Xinan ; SI Lu ; LIAN Bin ; MAO Lili ; TANG Bixia ; YAN Xieqiao ; ZHOU Li ; BAI Xue ; LI Siming ; JI Qing ; TIAN Hui ; GUO Jun
Chinese Journal of Cancer Biotherapy 2021;28(2):151-156
[Abstract] Objective: Elevated levels of soluble PD-L1 (sPD-L1) are associated with worse prognosis of renal cell carcinoma and
multiple myeloma. However, the regulatory roles and functions of sPD-L1 in advanced melanoma are not fully understood. This study
was designed to evaluate the association between circulating sPD-L1 concentrations and prognosis of patients with advanced acral or
mucosal melanoma. Methods: A total of 102 untreated patients with advanced acral and mucosal melanoma admitted to Peking
University Cancer Hospital between January 2012 and December 2015 were enrolled in this study. In the meanwhile, peripheral blood
samples were obtained from 40 healthy donors. Circulating sPD-L1 concentrations were determined using an enzyme-linked
immunosorbent assay. Results: The advanced melanoma cohort included 58 acral melanoma patients and 44 mucosal melanoma
patients. The pre-treatment concentration of sPD-L1 (2.91±2.23 ng/ml) in plasma of patients group was elevated as compared with that
in healthy donors (0.59 ng/ml). The concentration of sPD-L1 in serum was significantly upregulated in 39/102 (38.2%) patients and
significantly associated with increased LDH level (P=0.021) and number of Tregs (P=0.017). The overall survival rates of patients with
high or low concentrations of sPD-L1 were statistically different (8.5 months [high level] vs 11.6 months [low level], P=0.022).
Conclusion: sPD-L1 concentration is elevated in patients with advanced acral or mucosal melanoma, which may play an important role
in predicting prognosis.